OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway

BACKGROUND: Vismodegib (V) suppresses sonic hedgehog (SHH) signaling. We postulated that vismodegib together with chemotherapy may be more efficient than chemotherapy alone in patients (pts) relapsing of a SHH-activated medulloblastoma (MB). MATERIAL AND METHODS: Adult pts with recurrent SHH-MB not...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Frappaz, D, Barritault, M, Montané, L, Laigle-Donadey, F, Chinot, O, Le Rhun, E, Bonneville-Levard, A, Meyronnet, D, Garin, G, Pérol, D
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Oral Presentations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795008/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.031
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares